Reports for CRISPR Therapeutics AG
Credit rating information
Evaluation of credit rating with traffic light as risk indicator and other helpful data about the company.Find out more
Economic information
Comprehensive information about the economic situation of a company.Find out more
Payment collection information
Overview of current and past debt enforcement proceedings.Find out more
Shareholder Information
Find out which national and international companies the stock corporation you are interested in also holds shares in.Find out more
Company dossier as PDF
Contact information, changes in the company, turnover and employee figures, management, ownership, shareholding structure and other company data.Retrieve company dossier
About CRISPR Therapeutics AG
- CRISPR Therapeutics AG from Zug operates in the sector «Research and development» and is active.
- The management of the company CRISPR Therapeutics AG consists of 16 persons. The foundation of the company took place on 31.10.2013.
- The company has last modified its commercial register entry on 20.06.2025. All previous commercial register entries are available under «Notifications».
- The company's UID is CHE-494.642.722.
- 8 trademarks or applications for trademarks of the company CRISPR Therapeutics AG are registered at the IPI.
- Next to the company CRISPR Therapeutics AG there are 93 other active companies with an identical address. These include: Absci GmbH, ACT International AG, Ahlstrom Oyj, Helsinki, Zweigniederlassung Zug.
Management (16)
newest board members
Dr. Briggs William Morrison,
Christian Rommel,
Sandesh Mahatme,
Samarth Kulkarni,
Maria Fardis
newest authorized signatories
Dr. Briggs William Morrison,
Christian Rommel,
Sandesh Mahatme,
Naimish Patel,
Samarth Kulkarni
Executive board
Commercial register information
Entry in the commercial register
31.10.2013
Legal form
Company limited by shares (AG)
Legal headquarters of the company
Zug
Commercial Registry Office
ZG
Commercial register number
CH-270.3.014.931-8
UID/VAT
CHE-494.642.722
Sector
Research and development
Purpose (Original language)
Die Gesellschaft bezweckt die Forschung und Entwicklung auf dem Gebiet von pharmazeutischen Produkten, einschliesslich biologischen und biotechnologischen Produkten, sowie die Herstellung und Kommerzialisierung derartiger Produkte. Die Gesellschaft kann Patente, Urheberrechte, Marken und andere Immaterialgüterrechte sowie Lizenzen jeder Art erwerben, halten und veräussern. Die Gesellschaft kann alle kommerziellen, finanziellen und anderen Tätigkeiten ausüben, welche mit dem Zweck der Gesellschaft direkt oder indirekt im Zusammenhang stehen. Die Gesellschaft kann dabei insbesondere die Schaffung von langfristigem und nachhaltigem Wert durch die Gesellschaft und durch die von ihr kontrollierten Unternehmen berücksichtigen. Die Gesellschaft kann Beteiligungen an anderen Unternehmen im In- und Ausland erwerben, halten und veräussern. Sie kann Zweigniederlassungen und Tochtergesellschaften im In- und Ausland errichten. Die Gesellschaft kann Grundstücke erwerben, verwalten und veräussern sowie Vermögensanlagen anderer Art tätigen. Die Gesellschaft kann den von ihr kontrollierten und die sie kontrollierenden Gesellschaften Darlehen und andere direkte oder indirekte Finanzierungen gewähren und für deren Verbindlichkeiten Sicherheiten aller Art stellen, ein-schliesslich mittels Pfandrechten an oder fiduziarischen Übereignungen von Aktiven der Gesellschaft oder Garantien jedwelcher Art, ob entgeltlich oder nicht.
Auditor
Current auditor (1)
Name | City | Since | Until | |
---|---|---|---|---|
Ernst & Young AG | Basel | 05.11.2013 |
Other company names
Past and translated company names
- CRISPR Therapeutics SA
- CRISPR Therapeutics Ltd
- Crispr Therapeutics Ltd
- Crispr Therapeutics SA
- Crispr Therapeutics AG
- Inception Genomics AG
Branches (0)
Ownership structure
Holdings
Trademarks
Trademark | Registration date | Status | Number |
---|---|---|---|
CRISPR-X | - | pending application | 16108/2022 |
CRISPR-X | - | pending application | 16108/2022 |
Newest SOGC notifications: CRISPR Therapeutics AG
The latest updates from the Swiss Official Gazette of Commerce (SOGC) are available in the original language of the source commercial register office only. View all notifications
Publication number: HR02-1006361934, Commercial Registry Office Zug, (170)
CRISPR Therapeutics AG, in Zug, CHE-494.642.722, Aktiengesellschaft (SHAB Nr. 103 vom 30.05.2025, Publ. 1006344507).
Statutenänderung:
05.06.2025. [Änderung einer nicht publikationspflichtigen Tatsache.].
Ausgeschiedene Personen und erloschene Unterschriften:
Bruno, Julianne, amerikanische Staatsangehörige, in Wellesley (US), Zeichnungsberechtigte, mit Kollektivunterschrift zu zweien.
Eingetragene Personen neu oder mutierend:
Morrison, Briggs William, amerikanischer Staatsangehöriger, in Newton (US), Mitglied des Verwaltungsrates, mit Kollektivunterschrift zu zweien.
Publication number: HR02-1006344507, Commercial Registry Office Zug, (170)
CRISPR Therapeutics AG, in Zug, CHE-494.642.722, Aktiengesellschaft (SHAB Nr. 56 vom 21.03.2025, Publ. 1006288355).
Statutenänderung:
27.05.2025.
Aktienkapital neu:
CHF 2'752'439.91 [bisher: CHF 2'697'176.76].
Liberierung Aktienkapital neu:
CHF 2'752'439.91 [bisher: CHF 2'697'176.76].
Aktien neu:
91'747'997 vinkulierte Namenaktien zu CHF 0.03 [bisher: 89'905'892 vinkulierte Namenaktien zu CHF 0.03]. Ordentliche Kapitalerhöhung innerhalb des Kapitalbandes.
Publication number: UP04-0000007162, Commercial Registry Office Zurich
"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 13.05.2025/nPublicly viewable until: 13.05.2026/nPublication number: UP04-0000007162/nPublishing entity/nWalder Wyss AG, Seefeldstrasse 123.
8008 Zürich/nInvitation to the ordinary general meeting CRISPR/nTherapeutics AG/nOrganisation concerned:
/nCRISPR Therapeutics AG/nCHE-494.642.722/nBaarerstrasse 14/n6300 Zug/nGeneral meeting details:/n05.06.2025, 08.00 Uhr, at the offices of Walder Wyss Ltd./nInvitation/Agenda:/nInvitation to the Annual Shareholders' Meeting 2025/nTo the shareholders of CRISPR Therapeutics AG/nInvitation to the Annual General Shareholders' Meeting/nDate: June 5, 2025.
at 8:
00 a.m.
CEST/nPlace:
Offices of Walder Wyss Ltd., Seefeldstrasse 123,/n8008 Zurich.
Switzerland/nImportant Notice:
Please also read the accompanying proxy statement, which forms an/nintegral part of this notice.
The proxy statement contains in particular:
the statement of/nreasons for the below proposals of the board of directors of CRISPR Therapeutics AG/n(pages 47-55), details regarding admission to the meeting and persons eligible to vote/n(page 2), the voting procedure (pages 2-4) and details regarding the independent voting/nrepresentative (page 4)./nDear Shareholders:/nYou are cordially invited to the 2025 annual general meeting of shareholders, or the/n2025 Annual General Meeting, of CRISPR Therapeutics AG, or the Company, to be/nheld on June 5.
2025 at 8:
00 a.m. Central European Summer Time (2:00 a.m. East-/nern Daylight Time) as a physical meeting at the offices of Walder Wyss Ltd., See-/nfeldstrasse 123, 8008 Zurich, Switzerland. At the 2025 Annual General Meeting, the/nCompany's board of directors, or the Board of Directors, will propose to the Com-/npany's shareholders to consider and vote on the below matters. The Company's/ncommon shares are listed only on The Nasdaq Global Market and are traded under/nthe symbol ""CRSP""./nAgenda Items and Proposals of the Board of Directors:/n1. Approval of the Swiss Management Report, the Consolidated Finan-/ncial Statements and the Statutory Financial Statements of the Com-/npany for the year ended December 31, 2024./nThe Board of Directors proposes to the shareholders to approve the Swiss manage-/nment report, the consolidated financial statements and the statutory financial state-/nments of the Company for the year ended December 31, 2024 and to take note of/nthe reports of the auditors. Copies of these documents are available on the Internet/nat ir.crisprtx.com/swiss-statutory-financial-statements-and-audit-reports and availa-/nble for download at www.proxydocs.com/CRSP./n2. Approval of the Appropriation of Financial Results./nThe Board of Directors proposes to the shareholders to carry forward the net loss/nresulting from the appropriation of financial results as follows:/nProposed Appropriation of Net Loss: in Swiss Francs (""CHF"")/nBalance brought forward from previous years CHF (1,053,626,151)/nNet loss for the period (on a stand-alone unconsolidated/nbasis): CHF (332,051,209)/nTotal accumulated net loss: CHF (1,385,677,360)/nResolution proposed by the Board of Directors:/n- RESOLVED, that the net loss for the period of/nCHF 332,051,209 shall be carried forward./n3. Discharge of the Members of the Board of Directors and the Executive/nCommittee./nThe Board of Directors proposes to the shareholders that the members of the Board/nof Directors and the executive committee of the Company, or the Executive Commit-/ntee, be discharged from personal liability for the business year ended December 31,/n2024./n4. Election or Re-election of the Members to the Board of Directors and/nthe Chairman./nThe Board of Directors proposes to the shareholders that Samarth Kulkarni, Ph.D.,/nbe re-elected as member of the Board of Directors and as Chairman of the Board of/nDirectors and that each of Ali Behbahani, M.D.;
Maria Fardis, Ph.D.;
H. Edward Flem-/ning, Jr., M.D.;
Simeon J. George, M.D.;
John T. Greene;
Katherine A. High, M.D.;
/nSandesh Mahatme, LL.M.;
Christian Rommel, Ph.D.;
Douglas A. Treco, Ph.D. and/nBriggs W. Morrison, M.D., be, as applicable, elected or re-elected as directors, each/nfor a term extending until completion of the 2026 annual general meeting of share-/nholders. The election of Briggs W. Morrison is subject to approval of Proposal 8/nhereto (approval of increasing the maximum size of the Board of Directors). Infor-/nmation on the professional backgrounds and qualifications of each director nominee,/nas well as information on committee memberships, can be found under ""Board of/nDirectors and Corporate Governance-Election of Directors"" on pages 6-8 in the ac-/ncompanying proxy statement and is available at www.proxydocs.com/CRSP./n4.a Re-election of Samarth Kulkarni, Ph.D., as member and Chairman/n4.b Re-election of Ali Behbahani, M.D./n4.c Re-election of Maria Fardis, Ph.D./n4.d Re-election of H. Edward Fleming, Jr., M.D./n4.e Re-election of Simeon J. George, M.D./n4.f Re-election of John T. Greene/n4.g Re-election of Katherine A. High, M.D./n4.h Re-election of Sandesh Mahatme, LL.M./n4.i Re-election of Christian Rommel, Ph.D./n4.j Re-election of Douglas A. Treco, Ph.D./n4.k Election of Briggs W. Morrison, M.D./n5. Election or Re-election of the Members of the Compensation/nCommittee./nThe Board of Directors proposes to the shareholders to elect or re-elect, as appli-/ncable, each of Ali Behbahani, M.D., H. Edward Fleming, Jr., M.D., John T. Greene/nand Briggs W. Morrison, M.D. (subject to approval of Proposals 4 and 8 hereto) as/nmembers of the Compensation Committee of the Board of Directors, each for a term/nextending until completion of the 2026 annual general meeting of shareholders. In-/nformation on the professional backgrounds and qualifications of each director nom-/ninee can be found under ""Board of Directors and Corporate Governance-Election/nof Directors"" on pages 6-8 in the accompanying proxy statement and are available/nat www.proxydocs.com/CRSP./n5.a Re-election of Ali Behbahani, M.D./n5.b Re-election of H. Edward Fleming, Jr., M.D./n5.c Re-election of John T. Greene/n5.d Election of Briggs W. Morrison, M.D./n6. Approval of the Compensation for the Board of Directors and the Ex-/necutive Committee and Non-Binding Advisory Vote on the 2024 Com-/npensation Report./nThe Board of Directors proposes to the shareholders to hold the following separate/nvotes on the non-performance-related compensation and the variable compensation/nof the Board of Directors and the Executive Committee:/n6.a Binding vote on maximum non-performance-related compensation for/nmembers of the Board of Directors from the 2025 Annual General/nMeeting to the 2026 annual general meeting of shareholders./nThe Board of Directors proposes to the shareholders to approve the maximum/namount of non-performance-related compensation for the members of the Board of/nDirectors covering the period from the 2025 Annual General Meeting to the 2026/nannual general meeting of shareholders, i.e., USD $670,000 (cash based compen-/nsation)./n6.b Binding vote on maximum equity for members of the Board of Direc-/ntors from the 2025 Annual General Meeting to the 2026 annual general/nmeeting of shareholders./nThe Board of Directors proposes to the shareholders to approve the maximum grant/nof equity or equity linked instruments for the members of the Board of Directors/ncovering the period from the 2025 Annual General Meeting to the 2026 annual gen-/neral meeting of shareholders with maximum value of USD $12,389,198 (equity grant/ndate value)./n6.c Binding vote on maximum non-performance-related compensation for/nmembers of the Executive Committee from July 1, 2025 to June 30,/n2026./nThe Board of Directors proposes to the shareholders to approve the maximum/namount of non-performance-related cash compensation for the members of the Ex-/necutive Committee covering the period from July 1, 2025 to June 30, 2026, i.e., USD/n$3,700,579 (cash based compensation plus social security costs)./n6.d Binding vote on maximum variable compensation for members of/nthe Executive Committee for the current year ending December 31,/n2025./nThe Boar"
Hit list
Here you will find a link from the management to a hit list of persons with the same name who are registered in the commercial register.